Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical Inc. (BMRN) today and set a price target of $128. The company’s shares closed yesterday at $85.51.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.2% and a 32.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Liquidia Technologies Inc.
Currently, the analyst consensus on BioMarin Pharmaceutical Inc. is a Strong Buy with an average price target of $125.57, which is a 46.8% upside from current levels. In a report issued on June 10, Cantor Fitzgerald also maintained a Buy rating on the stock with a $131 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $106.74 and a one-year low of $79.13. Currently, BioMarin Pharmaceutical Inc. has an average volume of 1.33M.
Based on the recent corporate insider activity of 121 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMRN in relation to earlier this year. Most recently, in April 2019, Jean Jacques Bienaime, the CEO of BMRN bought 1,000 shares for a total of $21,510.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim.